FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

MCA 37-7-702 and 37-7-703 cover any pharmacy outside Montana that ships, mails or delivers dispensed legend drugs to a Montana resident, or that counsels Montana patients. Each must be registered or licensed with the Board. It must submit a good-standing certificate from its home-state licensing authority and identify a pharmacist, licensed in the home state, who is in charge of dispensing to Montana. ARM 24.174.1001, as amended effective 12/6/2025, adds: home-state licensure; registration with the Montana Secretary of State with a Montana registered agent; NABP Digital Pharmacy Accreditation 'if applicable and if eligible'; readily retrievable Montana dispensing records; reasonable pharmacist access; and a toll-free number on labels. MCA 37-7-706 requires the toll-free line at least 6 days and 40 hours a week. If the home state refuses the Board's inspection request, the Board may cancel the right to do business unless the pharmacy accepts a Montana onsite inspection (MCA 37-7-704). The Board's FAQ confirms the pharmacist in charge does not need a Montana license (ARM 24.174.1003).

Per the Board's rule notice, 2025 HB 794 renamed 'mail service' pharmacies to 'mail order' pharmacies; the MCA history cites Ch. 726, L. 2025. MAR 2025-206 repealed ARM 24.174.1002, including its old requirement of VIPPS accreditation for registrations after 2001, and moved the conditions into 24.174.1001. The LII copies of ARM 24.174.1001–1003 predate this and are outdated. Pending: MAR Notice No. 2026-131.1 (published 7/24/2026; hearing 8/14/2026; comments closed 8/21/2026) would require any facility doing sterile compounding, including out-of-state mail order pharmacies, to get a no-fee sterile compounding endorsement and name a USP <797> designated person. No adoption notice was on the Board's rule-notices page as of 9/23/2026.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

MCA 37-7-101(9) defines compounding as based on: a practitioner's prescription drug order; a practitioner–pharmacist–patient relationship; research or teaching; routine, regularly observed prescribing patterns; or registration as an FDA outsourcing facility. It does not mention office use. No current Montana Board rule was found that expressly allows or bans office-use compounding by a 503A pharmacy, so the law is silent. Proposed MAR Notice No. 2026-131.1 (hearing 8/14/2026) would add to ARM 24.174.841 and to a new nonsterile compounding rule that 'Pharmacies must comply with section 503A ... including but not limited to compounding pursuant to a valid patient specific prescription.' Under the same notice, office-stock distribution would go through outsourcing facilities holding a wholesale drug distributor license. That matches FDA's view.

Marked unknown because current Montana law is silent; both sources are primary. The proposed rule's hearing was 8/14/2026 and comments closed 8/21/2026. As of 9/23/2026, no adoption notice was on the Board's rule-notices page. Confirm with the Montana Board of Pharmacy, (406) 444-6880.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Under current law, MCA 37-7-605 requires out-of-state wholesale distributors, 3PLs, manufacturers and repackagers to be licensed before doing business in Montana. 'Wholesale distribution' means distribution to anyone other than a consumer or patient (MCA 37-7-602(7)). That definition adopts the federal exclusions in 21 U.S.C. §353(e)(4), which include distribution of a drug by its manufacturer. ARM 24.174.1202(6) issues manufacturer licenses only to facilities located in Montana. The current rules never say how an out-of-state 503B fits. MCA 37-7-101(29) defines 'outsourcing facility'. The Board's proposed NEW RULE 3 (MAR Notice No. 2026-131.1) would require any outsourcing facility doing sterile compounding to get a no-fee outsourcing endorsement. It would also need an out-of-state mail order pharmacy license to dispense patient-specific medications, or a wholesale drug distributor license to supply pharmacies or prescribers. The rule would further require FDA 503B registration, cGMP compliance and pharmacist supervision.

Marked unknown because current rules do not say how an out-of-state 503B is licensed; the pending rule would settle it. The Board's website lists these facility license types: community, institutional, out-of-state mail order, wholesale drug distributor, limited service and outpatient surgical center. There is no outsourcing-facility type. MAR 2026-131.1: hearing 8/14/2026, comments closed 8/21/2026. No adoption notice was seen as of 9/23/2026. ARM 24.174.1202 was amended again by MAR 2025-206 (eff. 12/6/2025), but paragraph (6) was unchanged in the proposal text. Confirm with the Montana Board of Pharmacy, (406) 444-6880.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Montana is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

MCA 50-32-301 requires anyone who manufactures, distributes or dispenses dangerous drugs (Montana's term for controlled substances) to register annually with the state, but MCA 50-32-303 directs the Board of Pharmacy to waive that registration for practitioners (other than pharmacies) who are registered or licensed by the federal government to dispense. The Board separately offers a Medical Practitioner Dispenser registration for physicians, PAs and APRNs who dispense take-home medications from their office; the Board's FAQ says that registration is not needed for prescribing, in-office administration or samples, and that controlled substances may not be dispensed under it. Montana prescribers must also register with the Montana Prescription Drug Registry (MPDR).

Waiver is statutory (MCA 2025 text confirmed). The Medical Practitioner Dispenser FAQ is dated 2022-03-15 (older than 2 years - possibly stale) and states CS may not be dispensed under that registration; in-office administration of CS is not covered by it. NP/PA: the waiver in 50-32-303 is not limited to physicians.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

MCA 37-7-1515 requires a prescriber or the prescriber's agent to review the patient's records in the prescription drug registry before issuing a prescription for an opioid or a benzodiazepine. Exemptions include hospice patients, prescriptions of 7 days or less with no refills, drugs lawfully administered in a health care facility, emergencies that prevent prior review, chronic pain patients whose records are reviewed at least every 3 months, and registry outages or technological failures that are reported. The registry is operated by the Montana Board of Pharmacy.

History: En. Sec. 3, Ch. 89, L. 2019. Text read via WebFetch summary of the official MCA page (the section heading and operative sentence were quoted; the exemption list was paraphrased by the fetch tool). The page could not be downloaded directly because of bot protection.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

MCA 37-2-104 allows a medical practitioner to dispense drugs within scope after registering with the Board of Pharmacy, at the practitioner's office, to the practitioner's own patients, with counseling offered and only as needed for the patient's condition. A practitioner may not dispense a controlled substance unless engaged in the practice of pharmacy under Title 37, chapter 7. Exceptions cover emergencies, no community pharmacy available, occasional dispensing, samples and verified pharmacy unavailability, plus family-planning clinic nurses, urban Indian clinics and opioid antagonists.

Most recently amended by Ch. 137, L. 2025; the practitioner registration route dates from 2021 (SB 374 per a vendor summary).

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) Treatment of a patient located in Montana by telemedicine occurs where the patient is, so the physician must be licensed in Montana; the statute exempts only out-of-state physicians who limit services to an occasional case and have no regular Montana office or hospital connections (MCA 37-3-103, per CCHP). (2) A provider-patient relationship may be established through telemedicine if the standard of care does not require an in-person encounter; the licensee must verify identities, establish the relationship before care and obtain a medical history sufficient for diagnosis before prescribing (ARM 24.156.813). (3) The rule expressly allows prescribing Schedule II drugs by telemedicine in compliance with DEA requirements; no Montana-specific telehealth limit on Schedule III drugs such as testosterone was found. (4) IMLC: member.

Rule amended effective 2024-02-10 (2024 MAR p. 273). MCA 37-3-103 read via CCHP only. Montana separately restricts practitioner dispensing of controlled substances (MCA 37-2-104, per CCHP), which is a dispensing rather than telehealth issue.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Board of Nursing's Medical Spa FAQ (created 2020-09-22) says a qualified health care provider must provide or appropriately supervise medical procedures and must prescribe injectables. RNs and LPNs with the appropriate training, education and supervision may inject prescribed medications as part of a medical treatment plan, but may not prescribe treatments or diagnose. APRNs have full practice authority to prescribe and perform services within their scope. No Montana rule requiring on-site supervision or a specific prior exam for cosmetic injections was found.

FAQ dates from 2020 (possibly stale) but is still linked from the Board's scope-of-practice page on 2026-09-23. 'Appropriate supervision' is not defined in the FAQ.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Montana Board of Nursing's scope-of-practice resources (checked 2026-09-23) include general scope guidelines and a medical spa FAQ but no IV-hydration guidance on prior exams, standing orders or mobile services.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

The Board of Nursing's Medical Spa FAQ says medical spas as facilities are not regulated by licensing boards and that a person not licensed by any board may own one, provided licensed staff practise within scope and qualified providers supervise and prescribe. Permit Health's 2025 guide rates Montana 'Moderate', citing Mont. Admin. R. 24.156.625(1)(t) (the statute was repealed in 1995), and MedPath Compliance calls it 'Yes (nuanced)', so physicians employed by lay-owned spas may face medical board scrutiny.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

In its Medical Spa FAQ the Board of Nursing states that laser hair removal is a medical procedure and may only be administered by a qualified health care provider acting within the provider's scope of practice, directing nurses to its scope-of-practice guidance to decide whether it fits their own scope. The FAQ describes medical spa services as those exceeding the scope of Board of Barbers and Cosmetologists licensees. No Montana laser-technician licence or medical board delegation rule for lasers was located.

Whether an RN may perform laser hair removal depends on the Board's scope-of-practice decision model; the Montana Board of Medical Examiners' position was not checked. Possibly stale (2020).

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Montana was not among them, but this research did not confirm its statutes. Montana's CLIA state agency is Montana DPHHS, Office of Inspector General, Certification Bureau (MTSSAD@mt.gov, 406-444-2099); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules. ASCLS lists Montana among the states that license clinical laboratory personnel, which applies to labs located in the state.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Montana's rule. Montana's lab regulator (CLIA state agency) is Montana DPHHS, Office of Inspector General, Certification Bureau (MTSSAD@mt.gov, 406-444-2099). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

SB 535 amended Montana's Right to Try Act (Title 50, ch. 12, MCA) and created DPHHS licensure of experimental treatment centers ($10,000 application, $5,000 annual renewal). 'Experimental treatment' means an investigational drug, biological product, device or other treatment that has completed Phase 1 and either remains in an FDA-approved trial or has a demonstrated safety record under department rules. Centers must put 2% of net annual profits toward access for qualifying Montana residents. Informed consent is required, and it may be written or recorded digitally. Licensing boards may not discipline providers solely for recommending or providing experimental treatment. The Act took effect on passage and approval. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Stem cell and exosome products qualify only if they meet the 'experimental treatment' definition (Phase 1 completed, plus an ongoing trial or a documented safety record); most commercial birth-tissue and exosome products do not have Phase 1 data. Check DPHHS rules for center licensing status.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Montana does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.